Eisai and Lilly were the biggest winners at the 19^th Annual Scrip Awards in a glittering ceremony at the Dorchester in London’s Mayfair, hosted by the actor and comedian Jon Culshaw.

Novartis' radioligand therapy has performed well against standard-of-care androgen-receptor pathway inhibitor therapy and could potentially be a paradigm shift in the treatment of prostate cancer.

The upcoming European Society for Medical Oncology meeting in Madrid has a full slate of potentially practice-changing late-breaking clinical trials ready to be presented. Here, Scrip takes a look at five of the most eagerly anticipated.

The first $1bn quarter since 2021 suggests that biotech’s IPO window is opening once more. But times remain tough, and many recently listed groups have seen their valuations fall.